Need for Integrative Science

Computational biology and biostatistics are becoming essential tools of drug hunters to successfully advance pre-clinical and clinical programs. The success of current biotechnology companies depends on their ability to combine quantitative approaches with biology, pharmacology and drug discovery for the mining of internal and external datasets. The core mission of Monoceros Biosystems is to offer this unique combination of skills and experience, traditionally only available to large pharma companies with teams of dedicated bioinformaticians, to drug discovery companies of any size. Our name “Monoceros” – the Greek word for unicorn – reflects this mission. From the rigorous design of experiments, to data analysis and interpretation, we provide tailored support for our clients’ needs.

Personalized Applications of Bioinformatics in Drug Discovery

An advantage that an in-house bioinformatics team brings, that using only traditional service-based CROs misses, is individualized data exploration and understanding for a specific companies’ target or therapeutic area and modality. Monoceros’ consulting teams fully collaborate with your teams in order to provide data analytics tailored directly to you. From target identification and the discovery of pharmacodynamic (PD) biomarkers, to explaining molecular mechanisms of action (MoA); from indications discovery and patient selection, to high-throughput technologies which are revolutionizing drug discovery R&D, Monoceros provides answers and analytics specific to, and interpretable by, your company.

Big Data Explosion

The big data explosion changed the landscape of biology, chemistry, and drug discovery. Novel technologies have revealed the unprecedented complexity of human diseases. Hundreds of thousands of human genomes have been sequenced in search for novel disease associations. Tens of thousands of cancer samples have been comprehensively profiled at the DNA, RNA and protein levels. Large catalogues of pre-clinical models such as cancer cell lines have been characterized and screened with thousands of drugs and RNAi technologies to uncover novel disease dependencies. The ability to mine this data allow scientists to uncover novel therapeutic targets as well as novel indications for existing drugs.